Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations (2020 - 2021)

Agios Pharmaceuticals (AGIO) posted Cash from Discontinued Operations of 4102000.0 for Q4 2021, up 60.24% on a QoQ basis from 10318000.0 in Q3 2021, and down 335.48% year-over-year from 1742000.0 in Q4 2020.

Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations (2020 - 2021) Analysis & Trends

Agios Pharmaceuticals' Cash from Discontinued Operations history runs 2 years deep, the most recent figure standing at 4102000.0 for Q4 2021.

  • Quarterly Cash from Discontinued Operations fell 335.48% year-over-year to 4102000.0 in Q4 2021, while the trailing twelve-month figure through Sep 2022 was 4102000.0 (up 95.31% YoY) and the FY2021 annual result came in at 93234000.0, down 99.15% from the prior year.
  • Cash from Discontinued Operations was 4102000.0 for Q4 2021 at Agios Pharmaceuticals, up from 10318000.0 in the prior quarter.
  • Across five years, Cash from Discontinued Operations topped out at 1742000.0 in Q4 2020 and bottomed at 48291000.0 in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Discontinued Operations (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Agios Pharmaceuticals 2.13 Bn 2.13 Bn 19.43 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2021 -4.10 Mn
Dec 31, 2021 -4.10 Mn
Sep 30, 2021 -10.32 Mn
Sep 30, 2021 -10.32 Mn
Jun 30, 2021 -48.29 Mn
Jun 30, 2021 -48.29 Mn
Mar 31, 2021 -30.52 Mn
Mar 31, 2021 -30.52 Mn
Dec 31, 2020 1.74 Mn
Dec 31, 2020 1.74 Mn
Sep 30, 2020 -11.59 Mn
Sep 30, 2020 -11.59 Mn
Jun 30, 2020 -10.39 Mn
Jun 30, 2020 -10.39 Mn
Mar 31, 2020 -26.58 Mn
Mar 31, 2020 -26.58 Mn